Encephalitis Drugs Market Outlook:
Encephalitis Drugs Market size was valued at USD 1.25 billion in 2024 and is projected to reach USD 2.85 billion by the end of 2037, rising at a CAGR of 6.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of encephalitis drugs is assessed at USD 1.34 billion.
The worldwide number of encephalitis patients remains significant, with almost 6.52 million. In Western countries, acute encephalitis cases reached 7.5 per 100,000 people yearly. Other than this, in tropical countries, annually, 6.2 cases occur per 100,000, and the most common is herpes simplex encephalitis. Additionally, Japanese encephalitis is prevailing in Southeast Asia, registering 68,500 cases yearly. The fatality rate for the encephalitis ranges from 21%-31%. In order to avoid long-term disabilities such as epilepsy and fatalities, vaccination and early treatment are imperative.
Additionally, the supply chain for the treatment of encephalitis includes the distribution and production of antiviral medication. The medication mainly includes ganciclovir and acyclovir, and associated medical devices. There has been a huge investment in research and development conducted by Encephalitis International in alliance with various health institutions to upgrade the treatment of encephalitis. Various governments are funding research initiatives and arranging yearly conferences to enable the exchange of knowledge among professionals. Additionally, organizations are collaborating with the World Health Organization and other healthcare bodies to develop a standard protocol for the treatment.
